Hematopoietic Cell Transplantation for Hodgkin Disease

Philip J. Bierman, Auayporn Nademanee

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Patients infected with HIV are more likely to develop Hodgkin disease (HD), and HD has been described following solid organ transplantation. The poor results of conventional-dose salvage therapy for relapsed and refractory HD have led to the use of high-dose therapy (HDT) followed by autologous bone marrow transplantation (BMT) and peripheral blood hematopoietic cell transplantation (PBHCT) for these patients. Radiation is an essential tool in the treatment of HD. The prognosis for children and adolescents with HD is better than for adults and most are cured with primary therapy. Allogeneic HCT may result in a graft-versus-Hodgkin effect similar to the graft-versus-leukemia effect observed after allogeneic HCT for leukemia. Several groups of investigators have explored the use of reduced-intensity conditioning (RIC) allogeneic HCT for HD to exploit potential Graft-versus-Hodgkin disease (GVHL) effects and to reduce transplant-related mortality.

Original languageEnglish (US)
Title of host publicationThomas' Hematopoietic Cell Transplantation
Subtitle of host publicationFifth Edition
PublisherWiley-Blackwell
Pages675-695
Number of pages21
Volume2-2
ISBN (Electronic)9781118416426
ISBN (Print)9781118416006
DOIs
StatePublished - Jan 1 2016

    Fingerprint

Keywords

  • Bone marrow transplantation
  • Graft-versus-host disease
  • Hematopoietic cell transplantation
  • High-dose therapy
  • Hodgkin disease
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bierman, P. J., & Nademanee, A. (2016). Hematopoietic Cell Transplantation for Hodgkin Disease. In Thomas' Hematopoietic Cell Transplantation: Fifth Edition (Vol. 2-2, pp. 675-695). Wiley-Blackwell. https://doi.org/10.1002/9781118416426.ch56